ITH12674

has neuroprotective activity; structure in first source

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

1.	Michalska, Patrycja: 3 articles (02/2020 - 02/2017)
2.	León, Rafael: 2 articles (02/2020 - 02/2017)
3.	Buendia, Izaskun: 2 articles (01/2020 - 02/2017)
4.	Campello, Laura: 1 article (02/2020)
5.	Cuenca, Nicolás: 1 article (02/2020)
6.	Fernández-Sánchez, Laura: 1 article (02/2020)
7.	García, Antonio G: 1 article (02/2020)
8.	Kutsyr, Oksana: 1 article (02/2020)
9.	Lax, Pedro: 1 article (02/2020)
10.	Maneu, Victoria: 1 article (02/2020)

1.	Neuroinflammatory Diseases 01/01/2020 - "Given the high impact of neuroinflammation in the pathogenesis of neurodegeneration, we foresaw to study the anti-inflammatory properties of ITH12674. " 01/01/2020 - "Thus, ITH12674 could be of potential interest for the treatment of diseases with chronic neuroinflammation."
2.	Neurodegenerative Diseases (Neurodegenerative Disease) 02/07/2020 - "At present, we are chemically optimising compound ITH12674 with the focus on improving its neuroprotective potential in retinal neurodegenerative diseases."
3.	Retinitis Pigmentosa (Pigmentary Retinopathy) 02/07/2020 - "New Nrf2-Inducer Compound ITH12674 Slows the Progression of Retinitis Pigmentosa in the Mouse Model rd10." 02/07/2020 - "We here tested the hypothesis that ITH12674 could slow the retinal degeneration that causes blindness in rd10 mice, a model of retinitis pigmentosa. "
4.	Retinal Degeneration 02/07/2020 - "We here tested the hypothesis that ITH12674 could slow the retinal degeneration that causes blindness in rd10 mice, a model of retinitis pigmentosa. "
5.	Brain Ischemia (Cerebral Ischemia) 02/10/2017 - "ITH12674 is a multitarget drug, designed to exert a dual "drug-prodrug" mechanism of action, able to induce the phase II antioxidant and anti-inflammatory response for the treatment of brain ischemia. "